Verona Pharma Plc (VRP) Given Average Rating of “Buy” by Brokerages
Verona Pharma Plc (LON:VRP) has been given an average rating of “Buy” by the six research firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have covered the stock in the last year is GBX 80.75 ($1.06).
A number of equities research analysts have recently issued reports on VRP shares. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 250 ($3.29) target price on shares of Verona Pharma Plc in a research note on Wednesday, November 8th. N+1 Singer reissued a “buy” rating on shares of Verona Pharma Plc in a report on Tuesday, November 7th. Finally, reissued a “buy” rating on shares of Verona Pharma Plc in a report on Tuesday, November 7th.
Verona Pharma Plc (LON:VRP) traded down GBX 1 ($0.01) during mid-day trading on Wednesday, hitting GBX 118 ($1.55). The stock had a trading volume of 2,000 shares, compared to its average volume of 41,323. Verona Pharma Plc has a fifty-two week low of GBX 100 ($1.32) and a fifty-two week high of GBX 199.50 ($2.62).
About Verona Pharma Plc
Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.